Yan Sun

10.5k total citations · 1 hit paper
113 papers, 4.2k citations indexed

About

Yan Sun is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Yan Sun has authored 113 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 48 papers in Oncology and 22 papers in Molecular Biology. Recurrent topics in Yan Sun's work include Lung Cancer Treatments and Mutations (22 papers), Head and Neck Cancer Studies (18 papers) and Lung Cancer Research Studies (13 papers). Yan Sun is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Head and Neck Cancer Studies (18 papers) and Lung Cancer Research Studies (13 papers). Yan Sun collaborates with scholars based in China, United States and United Kingdom. Yan Sun's co-authors include Yi‐Long Wu, Claire Watkins, Mark A. Socinski, Kell Østerlind, Vera Hirsh, Tony Mok, Radj Gervais, Jean‐Yves Douillard, Frances A. Shepherd and Edward S. Kim and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Yan Sun

105 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Yi‐Long Wu, Yan Sun et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yan Sun China	27	2.3k	2.1k	1.1k	502	346	113	4.2k
Tomomi Kamba Japan	27	1.0k 0.4×	1.2k 0.6×	1.3k 1.3×	635 1.3×	100 0.3×	152	3.3k
Norihiko Tsuchiya Japan	37	1.1k 0.5×	1.7k 0.8×	1.6k 1.5×	755 1.5×	119 0.3×	310	4.6k
Iulia Cristina Tudor United States	19	1.9k 0.8×	1.1k 0.5×	788 0.7×	750 1.5×	74 0.2×	51	3.8k
Naoyoshi Onoda Japan	34	1.8k 0.8×	899 0.4×	1.3k 1.2×	866 1.7×	205 0.6×	236	4.3k
Takeo Kosaka Japan	39	1.2k 0.5×	1.6k 0.7×	1.7k 1.6×	838 1.7×	81 0.2×	290	4.8k
Carlos D. Flombaum United States	24	749 0.3×	642 0.3×	590 0.6×	273 0.5×	373 1.1×	40	2.2k
Vânia Nosé United States	43	1.0k 0.4×	667 0.3×	1.3k 1.2×	396 0.8×	161 0.5×	138	5.7k
Kazuko Sakai Japan	41	2.7k 1.2×	2.3k 1.1×	2.0k 1.9×	1.3k 2.5×	51 0.1×	245	5.4k
Ralph V. Boccia United States	31	1.7k 0.7×	577 0.3×	1.2k 1.1×	249 0.5×	85 0.2×	193	4.2k
Lindsey Gumbrell United Kingdom	17	1.3k 0.5×	564 0.3×	932 0.9×	274 0.5×	79 0.2×	24	2.7k

Countries citing papers authored by Yan Sun

Since Specialization

Citations

This map shows the geographic impact of Yan Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Sun more than expected).

Fields of papers citing papers by Yan Sun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Sun. The network helps show where Yan Sun may publish in the future.

Co-authorship network of co-authors of Yan Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Sun. A scholar is included among the top collaborators of Yan Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Sun. Yan Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shao, Xiaonan, et al.. (2025). Application and progress of non-invasive imaging in predicting lung invasive non-mucinous adenocarcinoma under the new IASLC grading guidelines. Insights into Imaging. 16(1). 4–4.

Yu, Jingwei, Yan Sun, Tingting Liu, et al.. (2024). 651P Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors. Annals of Oncology. 35. S514–S514. 3 indexed citations

Sun, Yan, Rong Niu, Jianxiong Gao, et al.. (2024). PET/CT radiomics and deep learning in the diagnosis of benign and malignant pulmonary nodules: progress and challenges. Frontiers in Oncology. 14. 1491762–1491762. 3 indexed citations

Wang, Yujie, Dan Zhao, Qian Lü, et al.. (2022). Nutritional counseling was insufficient to maintain dietary intake and nutritional status in head and neck cancer patients undergoing radiotherapy: A historical control study for future intervention in China. Asia-Pacific Journal of Oncology Nursing. 9(4). 190–196. 5 indexed citations

Zhang, Changgong, Liying Gao, Chunmei Bai, et al.. (2022). Penpulimab plus anlotinib in patients with recurrent or metastatic head and neck squamous cell carcinoma after the failure of first-line platinum-based chemotherapy: A single-arm, multicenter, phase 2 study.. Journal of Clinical Oncology. 40(16_suppl). 6027–6027. 1 indexed citations

Yang, Yunpeng, Hao Wang, Shenhong Qu, et al.. (2021). 121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC). Annals of Oncology. 32. S1430–S1430. 8 indexed citations

Wang, Yujie, Qian Lü, Lichuan Zhang, et al.. (2020). Nutrition Impact Symptom Clusters in Patients With Head and Neck Cancer Receiving Concurrent Chemoradiotherapy. Journal of Pain and Symptom Management. 62(2). 277–285. 18 indexed citations

Yang, Yun, Jianji Pan, Lizhu Lin, et al.. (2020). 912MO A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study. Annals of Oncology. 31. S659–S659. 5 indexed citations

Jiang, Shiyu, Sheng Yang, Jianliang Yang, et al.. (2019). Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. BMJ Open. 9(5). e028589–e028589. 1 indexed citations

10.

Sun, Yan, et al.. (2017). The clinical efficacy of capecitabine combined with docetaxel in treatment of patients with locally advanced breast cancer and its influence on immune function. Zhongguo jiceng yiyao. 24(10). 1543–1546.

11.

Song, Aiping, et al.. (2016). Multifocal electroretinogram in non-pathological myopic subjects: correlation with optical coherence tomography. International Journal of Ophthalmology. 9(2). 286–91. 10 indexed citations

12.

Huang, Jing, Qingxia Fan, Ping Lu, et al.. (2016). Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study. Journal of Thoracic Oncology. 11(6). 910–917. 55 indexed citations

13.

Sun, Yan, et al.. (2016). Right atrial isomerism in children older than 3 years. SpringerPlus. 5(1). 1372–1372. 3 indexed citations

14.

Wang, Qin, Yan Qin, Peng Liu, et al.. (2016). Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era. Chinese Medical Journal. 129(23). 2780–2785. 4 indexed citations

15.

Hu, Xingsheng, Baohui Han, Aiqin Gu, et al.. (2014). A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer. 86(2). 207–212. 31 indexed citations

16.

Wu, Yi‐Long, Yan Sun, Caicun Zhou, et al.. (2013). Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients. Chinese Medical Journal. 126(24). 4624–4628. 4 indexed citations

17.

Wolff, Antonio C., Ann Lazar, Igor Bondarenko, et al.. (2012). Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. 31(2). 195–202. 222 indexed citations

18.

Klapholz, Marc, William T. Abraham, Jalal K. Ghali, et al.. (2009). The Safety and Tolerability of Darbepoetin Alfa in Patients with Anaemia and Symptomatic Heart Failure. European Journal of Heart Failure. 11(11). 1071–1077. 24 indexed citations

19.

McMurray, John J.V., Inder S. Anand, Rafael Díaz, et al.. (2009). Design of the Reduction of Events with Darbepoetin Alfa in Heart Failure (RED-HF): A Phase III, Anaemia Correction, Morbidity–Mortality Trial. European Journal of Heart Failure. 11(8). 795–801. 85 indexed citations

20.

Sun, Yan, et al.. (2009). Nonfunctional parathyroid carcinoma. Journal of Cancer Research and Clinical Oncology. 136(7). 969–974. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact